secwatch / observer
8-K filed April 30, 2024, 7:59 PM ET ticker SGMO CIK 0001001233
regulatory confidence high sentiment negative materiality 0.70

SANGAMO THERAPEUTICS, INC (SGMO): Nasdaq/NYSE listing notice — Sangamo receives Nasdaq deficiency notice for bid price below $1 per share

SANGAMO THERAPEUTICS, INC

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange
nasdaq
Notice
deficiency notice
Deficiency
minimum bid price
Rules
5450(a)(1), 5810(c)(3)(A)
Exact text from the filing
April 24, 2024, Sangamo Therapeutics, Inc. (the “Company”) received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. In accordance with Nasd
View on SEC.gov

97 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR
accession 0001628280-24-019337
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.